Chest
Volume 156, Issue 2, August 2019, Pages 323-337
Original Research: Pulmonary and CardiovascularPredicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies
Preliminary data were presented at the International Society for Heart and Lung Transplantation 37th Annual Meeting, April 5-8, 2017, San Diego, CA; The American Thoracic Society International Conference, May 19-24, 2017, Washington DC; and at The American Thoracic Society International Conference, May 18-23, 2018, San Diego, CA.
Under a Creative Commons license
open access
Key Words
ESC/ERS-derived risk assessment
pulmonary arterial hypertension
registry
REVEAL
risk score calculator
Abbreviations
6MWD
6-min walk distance
BNP
brain natriuretic peptide
COMPERA
Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension
Dlco
diffusing capacity of the lungs for carbon monoxide
eGFR
estimated glomerular filtration rate
ERS
European Respiratory Society
ESC
European Society of Cardiology
FC
functional class
FPHR
French Pulmonary Hypertension Registry
PAH
pulmonary arterial hypertension
PVR
pulmonary vascular resistance
RAP
right atrial pressure
REVEAL
Registry to Evaluate Early and Long-Term PAH Disease Management
SPAHR
Swedish Pulmonary Arterial Hypertension Register
TIMI
thrombolysis in myocardial infarction
WHO
World Health Organization
Cited by (0)
FUNDING/SUPPORT: Actelion Pharmaceuticals US, Inc. (A Janssen Pharmaceutical Company of Johnson and Johnson) is the sponsor of the Registry to Evaluate Early and Long-Term PAH Disease Management Registry and provided funding and support for the analysis presented.
© 2019 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.